Product Description
XL228 is a small molecule inhibitor of BCR-ABL, SRC and insulin-like growth factor type 1 receptor (IGF1R), which are associated with cancer cell proliferation, survival, and metastasis. The compound also inhibits the T315I mutant form of BCR-ABL, which is resistant to currently approved inhibitors. XL228 is a small molecule protein kinase inhibitor with potent activity against BCR-ABL, including the T315I mutant form which is resistant to currently approved BCR-ABL inhibitors. XL228 also inhibits IGF1R, SRC, FGFR1-3, and the Aurora kinases. (Sourced from: https://ir.exelixis.com/news-releases/news-release-details/exelixis-reports-positive-phase-1-data-xl228-ash-annual-meeting)
Mechanisms of Action: TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Exelixis
Company Location: ALAMEDA CA 94502
Company CEO: Michael M. Morrissey
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Chronic Lymphoid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Chronic Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| XL228-002 | P1 |
Terminated |
Lymphoma |
2010-12-01 |
|
| Ph+ ALL | P1 |
Terminated |
Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia |
2010-12-01 |